Adial Pharmaceuticals Secures Innovative Patent for Addiction Therapy
Adial Pharmaceuticals Secures Innovative Patent for Addiction Therapy
New patent covers claims focusing on methods for identifying genetic markers in patients with alcohol or opioid-related disorders.
This patent expands the identification of potential treatment candidates for AD04 administration based on the patient’s unique genetic profile.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for addiction and related disorders, has recently been issued patent number 12,226,401. This patent represents a significant milestone for Adial, expanding its genetic-based approach to diagnosing and treating alcohol use disorder and other drug dependencies.
The newly granted patent specifically addresses a method for identifying vital genetic markers in patients suffering from disorders related to alcohol or opioid use. Through the identification of certain genotypes, such as the AC genotype of rs17614942 in the HTR3B gene and the AG genotype of rs1150226 in the HTR3A gene, healthcare providers can develop customized treatment plans utilizing Adial's investigational new drug, AD04. This innovative strategy allows treatment to be individually tailored based on a patient’s distinct genetic makeup, moving away from the traditional one-size-fits-all model.
Cary Claiborne, CEO of Adial Pharmaceuticals, expressed enthusiasm about this advancement, stating, "This patent underscores our commitment to advancing scientifically grounded solutions for diagnosing and treating addiction. Our genetic-based approach has the potential to significantly change how alcohol and opioid dependence are managed. By focusing on the underlying molecular issues, we believe this personalized strategy can enhance treatment effectiveness and open new avenues for millions seeking help with addiction."
Overview of Adial Pharmaceuticals' Approach
Adial Pharmaceuticals specializes in creating effective therapies designed to treat addiction, recognizing the urgent need for innovative options. Their primary investigational product, AD04, functions as a genetically targeted serotonin-3 receptor antagonist. This therapeutic agent is aimed at addressing Alcohol Use Disorder (AUD) specifically in heavy drinkers.
Recently, Adial conducted the ONWARD™ pivotal Phase 3 clinical trial, which showcased promising results, indicating reduced heavy drinking among participants with specific target genotypes as identified by Adial's proprietary genetic testing method. The clinical trial did not report significant safety or tolerability issues, further emphasizing the viability of AD04 as a treatment option.
Potential Impacts on Other Addictive Disorders
Beyond alcohol dependency, AD04 holds promise for treating various other addictions, including Opioid Use Disorder, gambling addiction, and obesity. This broad potential highlights the versatility of Adial's therapeutic approach, which is rooted in genetic research. By leveraging genetic insight, the company aims to broaden treatment access and effectiveness across multiple dependency issues.
Invitation for Partnerships
Adial Pharmaceuticals is open to exploring partnerships that can accelerate their mission to help individuals struggling with addiction. Interested parties are encouraged to reach out for discussions on collaborative opportunities that can lead to impactful advancements in addiction treatment.
Frequently Asked Questions
What does the new patent from Adial Pharmaceuticals cover?
The patent focuses on methods for identifying genetic markers in patients to provide tailored treatment plans for addiction therapies.
How does AD04 fit into Adial's treatment strategy?
AD04 is a genetically targeted therapeutic agent developed to specifically treat Alcohol Use Disorder and improve outcomes based on individual genetic profiles.
What are the potential broader applications of AD04?
AD04 has potential applications in treating other addictions, such as Opioid Use Disorder, gambling addiction, and obesity.
Who is leading Adial Pharmaceuticals?
Cary Claiborne serves as the CEO of Adial Pharmaceuticals, guiding the company’s innovative approach to addiction treatment.
How can I learn more about partnership opportunities with Adial?
Those interested in partnership opportunities are encouraged to contact Adial Pharmaceuticals directly for discussions on collaboration possibilities.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
